Ayshe A. Beesen, MD

Assistant Professor, Neurology

(617) 638-5351
75 E. Newton St Collamore Building

Education

  • Mount Sinai School of Medicine, MD
  • Yale University, BS

Publications

  • Published on 12/2/2014

    Manning AT, Eaton A, Azu M, Sampson M, Patil S, Godfrey D, Beesen AA, Liberman L, Gemignani ML. Breast cancer screening at the Breast Examination Center of Harlem. Ann Surg Oncol. 2015; 22(6):2026-33. PMID: 25448800.

    Read at: PubMed
  • Published on 2/6/2013

    Taylor DM, Moser R, Régulier E, Breuillaud L, Dixon M, Beesen AA, Elliston L, Silva Santos Mde F, Kim J, Jones L, Goldstein DR, Ferrante RJ, Luthi-Carter R. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J Neurosci. 2013 Feb 6; 33(6):2313-25. PMID: 23392662.

    Read at: PubMed
  • Published on 8/17/2009

    Rudinskiy N, Kaneko YA, Beesen AA, Gokce O, Régulier E, Déglon N, Luthi-Carter R. Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons. J Neurochem. 2009 Oct; 111(2):460-72. PMID: 19686238.

    Read at: PubMed
  • Published on 10/15/2003

    Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003 Oct 15; 23(28):9418-27. PMID: 14561870.

    Read at: PubMed

View all profiles